🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

HealthCare Global Enterprises Limited HCG NSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.hcgoncology.com
Company Profile ↓
₹678.80
+21.95% 1Y
Mkt Cap₹10,134.63 Cr
P/E707.08
P/B7.37
52W High₹776.30
52W Low₹521.75
Book Value₹89.21
EPS (TTM)₹0.96

Company Overview

HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services comprising patient care, psychological support, nutrition and dietetics, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, translational and nuclear medicine, oncodermatology, anaesthesiology, paediatric and gynaecologic oncology, orthopaedic oncology, uro-oncology, infectious diseases, gastrointestinal and thoracic oncology, breast surgical oncology, clinical pharmacology, and pain and palliative services. In addition, the company operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care. Further, it provides oncology diagnostics services, including biomarker and translational research, and clinical research services under the Triesta Sciences brand; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 14.8% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹2,538.43 Cr (+14.4% YoY); net profit ₹13.76 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +14.4%, earnings -69.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 14.8%, profit CAGR -22.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:14.84%
1 Year:14.44%

Compounded Profit Growth

5 Years:-22.31%
1 Year:-69.02%

Stock Price Performance

1 Year:+21.95%
6 Months:+6.17%
3 Months:+19.53%
1 Month:+8.20%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 62% of range
₹521.75 ₹776.30
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)67.13 · Neutral
Price Performance
1M+8.20%
3M+19.53%
6M+6.17%
1Y+21.95%
Valuation vs Sector

P/E of 707.08 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 14.8% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading at a high P/E of 707.1.
  • Earnings shrank at -22.3% CAGR over 5 years.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
707.08
Industry PE
39.97
Forward P/E
47.39
PEG Ratio
-
Book Value
₹89.21
Price to Book
7.37
P/S
3.98
EV/EBITDA
23.82
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
14.84%
Profit 5Y
-22.31%
Revenue (YoY)
14.44%
Earnings (YoY)
-69.02%

Profitability & Returns

ROCE
7.00%
ROE
1.03%
ROA
0.35%
Profit Margin
0.54%
Op Margin
8.73%
Gross Margin
51.10%
EPS (Latest Qtr)
₹0.15
EPS (TTM)
₹0.96

Balance Sheet & Liquidity

Debt/Equity
1.30
Quick Ratio
1.06
Current Ratio
1.12
Debt
₹1,735.36 Cr
Total Assets
₹3,922.54 Cr
Current Assets
₹1,135.21 Cr
Working Capital
₹118.05 Cr

Ownership

Promoter Holding
70.64%
Chg in Prom Hold
-0.00%
FII / Inst Holding
16.51%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
₹10,134.63 Cr
Total Revenue (TTM)
₹2,538.43 Cr
EBITDA
₹447.66 Cr
Free Cash Flow
₹55.00 Cr
Operating Cash Flow
₹347.10 Cr
Shares Outstanding
₹14.93 Cr
Gross Margin
51.10%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 HCG HealthCare Global Enterprises Limited NSEPHARMA 678.80 707.08 ₹10,134.63 Cr 0.00% 7.00% 1.03% 14.84% -22.31%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 441.71 Cr460.68 Cr486.94 Cr469.87 Cr494.63 Cr525.58 Cr553.54 Cr558.57 Cr583.43 Cr611.80 Cr645.16 Cr631.18 Cr650.29 Cr
Cost of Revenue --------283.23 Cr294.89 Cr313.75 Cr315.69 Cr317.04 Cr
Gross Profit --------300.20 Cr316.91 Cr331.41 Cr315.49 Cr333.25 Cr
Operating Expenses 365.40 Cr386.37 Cr402.32 Cr391.26 Cr402.60 Cr434.68 Cr451.30 Cr470.19 Cr252.55 Cr267.03 Cr270.90 Cr266.53 Cr270.98 Cr
Operating Income 34.11 Cr33.30 Cr41.41 Cr34.45 Cr46.05 Cr43.89 Cr52.50 Cr31.86 Cr47.65 Cr49.88 Cr60.51 Cr48.96 Cr62.27 Cr
EBITDA 76.31 Cr74.31 Cr84.62 Cr78.61 Cr92.03 Cr90.90 Cr102.24 Cr88.38 Cr115.86 Cr115.30 Cr126.24 Cr99.36 Cr106.76 Cr
Interest Expense 25.63 Cr25.55 Cr26.89 Cr29.46 Cr26.84 Cr33.71 Cr35.98 Cr40.70 Cr44.17 Cr45.47 Cr43.62 Cr44.78 Cr42.70 Cr
Pretax Income 13.13 Cr10.52 Cr17.92 Cr11.06 Cr28.22 Cr18.99 Cr27.65 Cr-3.30 Cr13.62 Cr11.92 Cr19.82 Cr-6.07 Cr1.25 Cr
Tax Provision 7.48 Cr6.87 Cr7.14 Cr7.63 Cr4.76 Cr5.36 Cr6.97 Cr11.05 Cr6.85 Cr5.94 Cr-84.00 L1.83 Cr-2.79 Cr
Net Income 5.65 Cr3.65 Cr10.78 Cr3.43 Cr23.46 Cr13.63 Cr20.68 Cr7.75 Cr7.36 Cr4.75 Cr16.27 Cr-9.43 Cr2.17 Cr
Diluted EPS 0.570.520.920.391.440.821.220.470.520.341.15-0.680.15

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 519.00 Cr584.00 Cr700.00 Cr829.00 Cr976.00 Cr1,092.00 Cr1,009.00 Cr-1,676.05 Cr1,889.91 Cr2,218.14 Cr2,538.43 Cr
Cost of Revenue --------799.75 Cr909.99 Cr1,062.27 Cr1,241.37 Cr
Gross Profit --------876.29 Cr979.92 Cr1,155.87 Cr1,297.06 Cr
Operating Expenses 443.00 Cr499.00 Cr595.00 Cr713.00 Cr864.00 Cr936.00 Cr887.00 Cr-708.04 Cr822.48 Cr979.93 Cr1,075.44 Cr
Operating Income 37.00 Cr41.00 Cr48.00 Cr45.00 Cr27.00 Cr9.00 Cr-37.00 Cr-168.25 Cr157.44 Cr175.94 Cr221.62 Cr
EBITDA 76.00 Cr85.00 Cr105.00 Cr116.00 Cr112.00 Cr157.00 Cr122.00 Cr-302.75 Cr342.78 Cr422.86 Cr447.66 Cr
Interest Expense 34.00 Cr38.00 Cr23.00 Cr42.00 Cr70.00 Cr138.00 Cr119.00 Cr-94.39 Cr100.69 Cr154.56 Cr176.57 Cr
Pretax Income 3.00 Cr035.00 Cr27.00 Cr-33.00 Cr-119.00 Cr-229.00 Cr-44.88 Cr67.73 Cr56.96 Cr26.92 Cr
Tax Provision -1.68 Cr-011.90 Cr10.26 Cr2.31 Cr-5.95 Cr6.87 Cr-27.25 Cr26.39 Cr8.13 Cr4.14 Cr
Net Income 5.00 Cr2.00 Cr23.00 Cr17.00 Cr-31.00 Cr-125.00 Cr-221.00 Cr-29.35 Cr48.16 Cr44.41 Cr13.76 Cr
Diluted EPS 0.11-0.162.442.23-2.66-11.36-14.58-2.093.413.120.96

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 776.00 Cr1,043.00 Cr1,225.00 Cr1,440.00 Cr1,650.00 Cr2,246.00 Cr2,031.00 Cr-2,316.02 Cr2,707.50 Cr3,543.24 Cr3,922.54 Cr
Current Assets --------580.34 Cr679.85 Cr843.80 Cr1,135.21 Cr
Cash & Equivalents --------174.62 Cr272.61 Cr235.87 Cr536.05 Cr
Inventory --------38.29 Cr42.67 Cr53.02 Cr59.82 Cr
Receivables --------302.51 Cr294.03 Cr400.90 Cr420.70 Cr
Total Liabilities --------1,446.60 Cr1,842.38 Cr2,553.19 Cr2,512.33 Cr
Current Liabilities --------570.32 Cr743.71 Cr1,046.42 Cr1,017.16 Cr
Long Term Debt --------361.74 Cr485.30 Cr604.58 Cr599.19 Cr
Total Debt 349.00 Cr324.00 Cr420.00 Cr464.00 Cr658.00 Cr1,347.00 Cr977.00 Cr-901.20 Cr1,274.36 Cr1,837.22 Cr1,735.36 Cr
Total Equity 280.00 Cr426.00 Cr433.00 Cr515.00 Cr477.00 Cr382.00 Cr697.00 Cr-860.52 Cr825.78 Cr922.44 Cr1,331.97 Cr
Shares Outstanding --------14.00 Cr14.02 Cr14.03 Cr14.93 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 60.00 Cr73.00 Cr91.00 Cr98.00 Cr98.00 Cr130.00 Cr121.00 Cr-251.59 Cr284.58 Cr317.11 Cr347.10 Cr
Investing Cash Flow -79.00 Cr-204.00 Cr-210.00 Cr-283.00 Cr-238.00 Cr-101.00 Cr-171.00 Cr--133.03 Cr-225.73 Cr-487.75 Cr-177.47 Cr
Financing Cash Flow 22.00 Cr216.00 Cr89.00 Cr161.00 Cr84.00 Cr-58.00 Cr112.00 Cr--140.07 Cr-64.02 Cr-42.44 Cr240.67 Cr
Capital Expenditure -80.00 Cr-210.00 Cr-192.00 Cr-256.00 Cr-188.00 Cr-107.00 Cr-36.00 Cr--133.24 Cr-185.68 Cr-208.87 Cr-292.10 Cr
Free Cash Flow -20.00 Cr-137.00 Cr-101.00 Cr-158.00 Cr-90.00 Cr23.00 Cr85.00 Cr-118.35 Cr98.90 Cr108.24 Cr55.00 Cr
Net Change in Cash 2.00 Cr85.00 Cr-29.00 Cr-24.00 Cr-56.00 Cr-30.00 Cr62.00 Cr--21.51 Cr-5.16 Cr-213.08 Cr410.30 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------52.3%51.9%52.1%51.1%
Operating Margin % 7.1%7.0%6.9%5.4%2.8%0.8%-3.7%-10.0%8.3%7.9%8.7%
Net Margin % 1.0%0.3%3.3%2.1%-3.2%-11.4%-21.9%-1.8%2.5%2.0%0.5%
ROE % 1.8%0.5%5.3%3.3%-6.5%-32.7%-31.7%-3.4%5.8%4.8%1.0%
ROCE % --------9.6%8.0%7.0%7.6%

Shareholding Pattern

Insiders
70.64%
Institutions
16.51%
Public Float
56.24%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for HCG

Google News hu, 25 Jun 2026

HCG Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE42bmRVY2UzOEFEQ1JhTmFvd19kZ2NmTmVTSG9LVEtSS21PbmlyWTBWMUs0MXVYZWktNVVQQVdoOG9Jc1VET2dSZE03dG5YN0FlVUlvOVhfTy11RUJvWWZfdFBpbURFbnZ5dXJlMkM3Nm9XMVBK?oc=5" target="_blank">HCG Forecas…

Google News Fri, 10 Jul 2026

Healthcare Global Enterprises Ltd. Share Price Live Today - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPdEJtMHhnVm5YWTZ3dHdGZEN5bDRpWTFMQUVSb1BaMDM4cVhiLTNjbU9LNGFvSTFnalZoUWVYdjFiam9WQ0d5bkE4QVpJOWVmTXVXMkNfUGd6aDJ2SDdqR1I4djhKc0xhZ1FwejY0bVBSbG1acTc3cHYzck8tSjFUQXNtNnJtbWloaUhDd2…

Google News hu, 09 Jul 2026

HCG shareholders approve ESOS 2026 via postal ballot - scanx.trade

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQVGdlbTZsWmU4UGhoRlpYMFZubDJCYktVc2ZZQWlGMk0yYWFSMnE0OTF3NF9HZWtleWJmSlJiYnY5T1VsOWR0RnhQTTcyRHBrWDI4Z3drUmdZRG84cDdUVzl1MndWSE1tSEZlSXN2NjR4OWs1eU5OX2FpbkRzVGRXd3hnMm5KX1NhUXQtbV…

Google News Wed, 25 Feb 2026

HCG RAISES ₹424 CR THROUGH RIGHTS ISSUE - ICICI Direct

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNejA4cG03ME5oV1FFRnlPdjRaQ3U0eHVPMER5S0lMWU9vNXFSOUJWeGE1UVprYzBwNExoOGlQS3RVZk9UbkQtTG40SUh2T1A2ODd3bzhjZy1ZYnJLT1kzd2R2QVJKMDFNMFhiVVM0RS02U29DTFhvSzlVUWdwcHQ5bk5aMjJUbTFQSmhyZ3…

Google News Wed, 18 Feb 2026

HealthCare Global board OKs rights issue proposal worth Rs 425 crore - Business Standard

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxOSEVwckdZM3M1VHNnM2xzQnlFNTlnY2kzMHBYNkhCelhSdWtINXB6akh5NzR0aGpsbkhOalpJNVNpSmRvYTZMbFpNTFozbEY4eTBRUEV2dFF4MzM4Qkt4eDdPNUxDMGtyU05pV0wzdzctcEtZcndWQkpDMkFDdlVZV1k0NG1DR1VUZ3hqcG…

Google News Mon, 12 Jan 2026

HCG | 1810.TW Stock Price & Real-time Quotes - finance.biggo.com

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE42Z05GSVAwMHJfdjhnc0FPVHlhOUlQQXBFUVR1aUh2eWY5bU9kbTBjRmZtc1BUQndrQlZNc2t4OFBCQ2w4S1JQNEZUQTJianky?oc=5" target="_blank">HCG | 1810.TW Stock Price & Real-time Quotes</a>&nbsp;&nbsp…

HCG — Frequently Asked Questions

What is the current share price of HealthCare Global Enterprises Limited (HCG)?

As of 2026-07-15 09:52 IST, HealthCare Global Enterprises Limited (HCG) trades at ₹678.80 on NSE. Its 52-week range is ₹521.75 to ₹776.30.

What is the market capitalisation of HCG?

HealthCare Global Enterprises Limited (HCG) has a market capitalisation of ₹10,134.63 Cr on NSE.

What is the P/E ratio of HCG?

HCG trades at a trailing price-to-earnings (P/E) ratio of 707.08. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 7.37.

What is the return on equity (ROE) of HCG?

HCG has a return on equity (ROE) of 1.03%. Its return on capital employed (ROCE) is 7.00%.

Is HCG a good stock to buy?

This page provides a data-driven analysis of HealthCare Global Enterprises Limited (HCG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space